A Phase II Study of Type-1 Polarized Dendritic Cell (aDC1) -Based Treatment in Combination With Tumor-Selective Chemokine Modulation (CKM: Interferon Alpha 2b, Rintatolimod and Celecoxib) in Melanoma Patients With Primary PD-1/PD-L1 Resistance

This phase II trial studies how well polarized dendritic cell (aDC1) based therapy, interferon alpha-2, rintatolimod, and celecoxib work together in treating patients with HLA-A2 positive (+) melanoma that has not responded to previous treatment (refractory). The aDC1 cell-based treatment contains white blood cells (dendritic cells or DCs) that stimulates the immune system. Interferon alpha-2 can improve the body's natural response to infections and other diseases. It can also interfere with the division of cancer cells and slow tumor growth. Rintalolimid may stimulate the immune system. Celecoxib is a drug that reduces pain. This study is being done to find out if the combination of the study cell-based treatment (aDC1 dendritic cells) and interferon alpha-2, rintatolimod, and celecoxib can prevent the growth and/or progression of melanoma.

开始日期2024-11-20

申办/合作机构

Roswell Park Comprehensive Cancer Center

[+1]

NCT04379518 / Suspended临床1/2期IIT

Phase 1/2A Study of Rintatolimod and IFN Alpha Regimen in Cancer Patients With COVID-19

This phase I/IIa trial studies the best dose and side effects of rintatolimod and interferon (IFN) alpha-2b in treating cancer patients with COVID-19 infection. Interferon alpha is a protein important for defense against viruses. It activates immune responses that help to clear viral infection. Rintatolimod is double stranded ribonucleic acid (RNA) designed to mimic viral infection by stimulating immune pathways that are normally activated during viral infection. Giving rintatolimod and interferon alpha-2b may activate the immune system to limit the replication and spread of the virus.

开始日期2020-11-17

申办/合作机构

Roswell Park Comprehensive Cancer Center

[+1]

NCT03899987 / Suspended临床2期IIT

Randomized Phase 2 Study: Neoadjuvant Conditioning of Prostate Cancer Tumor Microenvironment Using a Novel Chemokine-Modulating Regimen

This phase II trial studies how well aspirin and rintatolimod with or without interferon-alpha 2b work in treating patients with prostate cancer before surgery. Aspirin may help to keep the prostate cancer from coming back. Rintatolimod may stimulate the immune system and interfere with the ability of tumor cells to grow and spread. Interferon-alpha 2b may improve the body's natural response to infections and may slow tumor growth. It is not yet known how well rintatolimod, aspirin, and interferon-alpha 2b work in treating patients with prostate cancer undergoing surgery.

开始日期2019-11-29

申办/合作机构

Roswell Park Comprehensive Cancer Center

[+1]

100 项与干扰素α-2b生物类似药(Probiomed SA de CV) 相关的临床结果

登录后查看更多信息

100 项与干扰素α-2b生物类似药(Probiomed SA de CV) 相关的转化医学

登录后查看更多信息

100 项与干扰素α-2b生物类似药(Probiomed SA de CV) 相关的专利（医药）

登录后查看更多信息

100 项与干扰素α-2b生物类似药(Probiomed SA de CV) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L03AB05	-

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
尖锐湿疣	墨西哥	Probiomed SA de CV	2006-03-01
毛细胞白血病	墨西哥	Probiomed SA de CV	2006-03-01
乙型肝炎	墨西哥	Probiomed SA de CV	2006-03-01
丙型肝炎	墨西哥	Probiomed SA de CV	2006-03-01
卡波西肉瘤	墨西哥	Probiomed SA de CV	2006-03-01
黑色素瘤	墨西哥	Probiomed SA de CV	2006-03-01
多发性骨髓瘤	墨西哥	Probiomed SA de CV	2006-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00126594 (CTgov)	临床2期	转移性肾细胞癌	80	Laboratory Biomarker Analysis+Sorafenib Tosylate (Sorafenib Tosylate)	鏇鏇膚廠獵壓積顧鬱夢(壓齋醖選憲壓繭艱觸鏇) = 廠積餘襯遞鬱淵鹽鹽鹽鬱鑰夢構蓋窪鏇夢鏇蓋 (糧鹽積鏇網積淵壓膚艱, 鏇醖願觸製網鏇範衊獵 ~ 齋鑰鏇鏇窪艱築遞鑰網) 更多	-	2016-09-16
				Laboratory Biomarker Analysis+Sch 30500+Heberon Alfa+Urifron+Sorafenib Tosylate (Sorafenib Tosylate, Recombinant Interferon Alfa-2b)	鏇鏇膚廠獵壓積顧鬱夢(壓齋醖選憲壓繭艱觸鏇) = 鑰獵齋廠鑰憲觸膚選襯鬱鑰夢構蓋窪鏇夢鏇蓋 (糧鹽積鏇網積淵壓膚艱, 繭鬱窪遞夢艱網夢選構 ~ 鑰夢範膚齋範鹹齋憲襯) 更多